# A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.

> **NCT07215702** · PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 124 (estimated)

## Conditions studied

- Sepsis
- Acute Kidney Injury

## Interventions

- **DRUG:** AZD4144
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07215702
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-10
- **Primary completion:** 2027-02-11
- **Final completion:** 2027-02-11
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07215702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07215702, "A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07215702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*